It has also been approved for adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor [46]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.